DeepMed Research

IPSEN, OOO

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

Description of Sign-and-symptom Associations at Acromegaly Diagnosis.

Completed

Conditions: Acromegaly

First Posted Date: 2013-12-16

Last Posted Date: 2019-08-05

Lead Sponsor: Ipsen

Target Recruit Count: 648

Registration Number: NCT02012127

Locations: 🇫🇷
Hôpital de la Timone, Marseille, France
🇫🇷
Hôpitaux de Brabois, Nancy, France
🇫🇷
CHR Orléans - Hôpital la Source, Orléans, France

and more 22 locations

A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months

Completed

Conditions: Deep Infiltrating Endometriosis (DIE)

Interventions: Drug: Triptorelin Acetate 3.75mg intramuscular injection

First Posted Date: 2013-09-16

Last Posted Date: 2018-12-06

Lead Sponsor: Ipsen

Target Recruit Count: 402

Registration Number: NCT01942369

Locations: 🇨🇳
Chinese PLA General Hospital, Beijing, China
🇨🇳
Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China
🇨🇳
Shenzhen People's Hospital, Shenzhen, China

and more 15 locations

Somatuline Predictive Factors in Acromegaly and NET

Completed

Conditions: Acromegaly
Neuroendocrine Tumours

Interventions: Drug: Somatuline Autogel® 60, 90 or 120 mg

First Posted Date: 2013-04-25

Last Posted Date: 2019-01-14

Lead Sponsor: Ipsen

Target Recruit Count: 156

Registration Number: NCT01840449

Locations: 🇩🇪
ENDOC, Hamburg, Germany
🇦🇹
University Hospital of Vienna, Vienna, Austria
🇨🇭
University Hospital Basel, Basel, Switzerland

BN83495 Phase I in Post-menopausal Women

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Irosustat (BN83495)

First Posted Date: 2013-04-25

Last Posted Date: 2019-11-22

Lead Sponsor: Ipsen

Target Recruit Count: 50

Registration Number: NCT01840488

Locations: 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷
Institut Georges François Leclerc, Dijon, France
🇫🇷
Centre Eugène Marquis, Rennes, France

and more 2 locations

Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation)

Completed

Conditions: Post-stroke Arm Spasticity

First Posted Date: 2013-04-25

Last Posted Date: 2020-03-31

Lead Sponsor: Ipsen

Target Recruit Count: 302

Registration Number: NCT01840475

Longitudinal Study for Treatment With Botulinum Toxin A Injections in naïve and Pre-treated Patients Suffering From Cervical Dystonia [CD-NIS-Longterm]

Completed

Conditions: Cervical Dystonia

First Posted Date: 2013-04-25

Last Posted Date: 2019-01-14

Lead Sponsor: Ipsen

Target Recruit Count: 372

Registration Number: NCT01840462

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Phase 1

Completed

Conditions: Metastatic Breast Cancer With Active Brain Metastasis
Solid Tumors
ER/PR Positive Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: Ferumoxytol
Drug: MM-398

First Posted Date: 2013-01-17

Last Posted Date: 2019-11-27

Lead Sponsor: Ipsen

Target Recruit Count: 45

Registration Number: NCT01770353

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
University of Michighan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 4 locations

A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin 11.25 mg

First Posted Date: 2012-12-20

Last Posted Date: 2020-12-09

Lead Sponsor: Ipsen

Target Recruit Count: 226

Registration Number: NCT01753297

Locations: 🇨🇳
Chinese PLA General HospitalDepartment of UrologySite #156007, Beijing, China
🇨🇳
West China Hosspital, Sichuan UniversityDepartment of Urology Site #156008, Chengdu, China
🇨🇳
The First Affiliated Hospital of the 3th Military Medical University of PLA (Southwest Hospital) Site # 156010, Chongqing, China

and more 15 locations

Phase IV-Cervical Dystonia-INTEREST IN CD2

Completed

Conditions: Cervical Dystonia

Interventions: Biological: Botulinum toxin type A

First Posted Date: 2012-12-20

Last Posted Date: 2020-11-05

Lead Sponsor: Ipsen

Target Recruit Count: 1050

Registration Number: NCT01753349

Locations: 🇮🇱
Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
🇭🇺
Jósa András Oktató Kórház, Nyíregyháza, Hungary
🇵🇹
Centro Hospitalar Lisboa Norte, Lisbon, Portugal

and more 110 locations

Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.

Phase 3

Completed

Conditions: Cervical Dystonia

Interventions: Biological: Botulinum toxin type A
Drug: Placebo

First Posted Date: 2012-12-20

Last Posted Date: 2019-08-07

Lead Sponsor: Ipsen

Target Recruit Count: 134

Registration Number: NCT01753310

Locations: 🇺🇸
Loma Linda University Healthcare, Department of Neurology, Loma Linda, California, United States
🇺🇸
Guilford Neurologic Associates, West Palm Beach, Florida, United States
🇺🇸
NeuroTrials Research Inc., Atlanta, Georgia, United States

and more 39 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy